Wuhan Keqian Biology Co.,Ltd (SHA:688526)
China
· Delayed Price · Currency is CNY 14.68
+0.15 (1.03%)
Apr 29, 2026, 3:00 PM CST
SHA:688526 Revenue
In the year 2025, Wuhan Keqian Biology Co.,Ltd had annual revenue of 949.74M CNY with 0.83% growth. Wuhan Keqian Biology Co.,Ltd had revenue of 211.88M in the quarter ending December 31, 2025, a decrease of -23.35%.
Revenue
949.74M
Revenue Growth
+0.83%
P/S Ratio
7.17
Revenue / Employee
999.73K
Employees
922
Market Cap
6.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 949.74M | 7.82M | 0.83% |
| Dec 31, 2024 | 941.92M | -122.15M | -11.48% |
| Dec 31, 2023 | 1.06B | 62.81M | 6.27% |
| Dec 31, 2022 | 1.00B | -101.75M | -9.22% |
| Dec 31, 2021 | 1.10B | 259.79M | 30.81% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.95B |
| Suzhou Fengbei Biotech Stock | 3.17B |
| Jiangsu Aidea Pharmaceutical Group | 719.17M |
| R&G PharmaStudies | 896.26M |
| Shanghai OPM Biosciences | 354.91M |
| Innovita Biological Technology | 422.03M |
| Xiangxue Pharmaceutical | 1.60B |
| Chengdu Kanghua Biological Products | 1.20B |